Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

AL Amyloidosis Market to Showcase Growth at a CAGR of 7.24% by 2032 | DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

03 Oct, 2022, 19:24 GMT

Share this article

Share toX

Share this article

Share toX

The AL amyloidosis market is expected to show positive growth owing to the factors such as increased incidence and the anticipated launch of novel therapies during the forecast period (2019–2032).

LAS VEGAS, Oct. 3, 2022 /PRNewswire/ -- DelveInsight's AL Amyloidosis Market Insights report includes a comprehensive understanding of current treatment practices, AL amyloidosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Takeaways from the AL Amyloidosis Market Report

  • As per DelveInsight analysis, the AL amyloidosis market size in the 7MM was approximately USD 920 million in 2021.
  • As per the estimates, the total AL amyloidosis incident cases in the 7MM were approximately 8.6K in 2021. 
  • Globally, leading AL amyloidosis companies such as Merck & Co, Janssen Pharmaceutical, Caelum Biosciences, Oncopeptides AB, Bristol-Myers Squibb, Acrotech biopharma, Sanofi, Astellas Pharma GmbH, Prothena, Alexion Pharmaceuticals, Celgene Corporation, and others are developing novel AL amyloidosis drugs that can be available in the AL amyloidosis market in the coming years.
  • The promising AL amyloidosis therapies in the pipeline include Daratumumab, Birtamimab, CAEL-101, Melflufen, Elotuzumab, Evomela, Pomalidomide, and others.
  • In recent decades, the current understanding of AL amyloidosis has improved, leading to growing awareness, improved management, and better outcomes.

Discover which therapies are expected to grab the major AL amyloidosis market share @AL Amyloidosis Market Report

AL Amyloidosis Overview

Amyloid light chain (AL) amyloidosis, often known as primary amyloidosis, is the most frequent kind of systemic amyloidosis. Historically, systemic light-chain (AL) amyloidosis was assumed to be an inescapable fatal disease. Prior to successful therapies for the underlying plasma cell dyscrasia, the AL amyloidosis prognosis was poor, with an estimated AL Amyloidosis life expectancy of 13 months and just 6 months for those with symptomatic cardiac involvement. Current AL amyloidosis staging approaches focus on indicators of myocardial cell damage and heart failure indicators, which are very sensitive to cardiac involvement in amyloidosis.

AL amyloidosis symptoms do not appear until the disease has advanced. The appearance of signs and symptoms is influenced by which organ is afflicted. Swelling of the ankles and legs, acute weariness and weakness, shortness of breath with minimum exercise, diarrhea, perhaps with blood, or constipation, numbness, tingling, or pain in the hands or feet, and others are the common AL amyloidosis symptoms.

AL Amyloidosis Epidemiology Segmentation

DelveInsight estimates that there were approximately 8.6K incident cases of AL amyloidosis in the 7MM in 2021.

Among the EU5 countries, Germany had the highest number of AL amyloidosis incident cases in 2021.

The AL amyloidosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Incident Cases of AL Amyloidosis
  • Gender-specific Cases of AL Amyloidosis
  • Age-specific Cases of AL Amyloidosis

Download the report to understand which factors are driving AL amyloidosis epidemiology trends @AL Amyloidosis Epidemiological Insights

AL Amyloidosis Treatment Market 

The goal of AL amyloidosis treatment is to rapidly reduce the plasma cell clone to restore organ function by increasing amyloid reabsorption, hence improving heart function, patients' QOL, and survival. Chemotherapy (both standard and high dosage) coupled with autologous hematopoietic stem cell transplantation (ASCT) effectively reduces amyloid light chain development in appropriate people. Individuals who are ineligible for ASCT should be treated with melphalan, dexamethasone, and bortezomib-based regimens (BMDex). The National Comprehensive Cancer Network recommends high-dose melphalan followed by ASCT as one AL amyloidosis treatment option.

AL amyloidosis treatment is highly individualized, based on age, organ dysfunction, and regimen toxicity, and should be guided by hematologic and cardiac response indications. Almost two-thirds of patients benefit from alkylator-based chemotherapy. Novel agents are also in use, and trials to discover the best approach to utilize them are ongoing.

To know more about AL amyloidosis treatment options, visit @New Treatment for AL Amyloidosis 

AL Amyloidosis Pipeline Therapies and Key Companies

  • Daratumumab: Janssen Pharmaceutical
  • Birtamimab: Prothena
  • CAEL-101: Alexion Pharmaceuticals
  • Melflufen: Oncopeptides AB
  • Elotuzumab: Bristol-Myers Squibb
  • Evomela: Acrotech Biopharma
  • Pomalidomide: Celgene Corporation

Learn more about the FDA-approved drugs for AL amyloidosis treatment @Drugs for AL Amyloidosis Treatment 

AL Amyloidosis Market Dynamics

The AL amyloidosis market dynamics are anticipated to change as a result of an increase in awareness and collaboration among key industry participants (commercialization of Darzalex Faspro by Genmab and Janssen Biotech, acquisition of Caelum Biosciences by AstraZeneca in 2021). Furthermore, The robust pipeline with a novel, first-in-class therapies for AL amyloidosis treatment is one of the primary factors propelling the AL amyloidosis market growth.

However, epidemiological data on AL amyloidosis is lacking, and retroactive analysis diminishes the data's legitimacy, restricting the expansion of the AL amyloidosis market. Furthermore, the diseases' complicated heterogeneity causes delays in diagnosis, resulting in severe disease (organ dysfunction - heart, kidney, liver), reducing AL amyloidosis survival rates, and serving as a barrier to the growth of the AL amyloidosis market. 

Moreover, due to poor patient recruitment and a lack of clearly defined new outcomes, AL amyloidosis clinical trials are challenging to conduct. The involvement of the cardiac and renal organs leads to a high treatment cost. In addition, the expected launches are likely to be more expensive than myeloma-based drugs, restricting the availability and affordability of AL amyloidosis treatments. Furthermore, in the age of daratumumab-based frontline treatment, the role of upfront ASCT in eligible patients must be clarified. As a result, the aforementioned factors impede the AL amyloidosis market growth.

Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Base Year 

2021

Market CAGR

7.24 %

Market Size in 2021

USD 920 Million

Key AL Amyloidosis Companies

Merck & Co, Janssen Pharmaceutical, Caelum Biosciences, Oncopeptides AB, Bristol-Myers Squibb, Acrotech biopharma, Sanofi, Astellas Pharma GmbH, Prothena, Alexion Pharmaceuticals, Celgene Corporation, and others

Key AL Amyloidosis Therapies

Daratumumab, Birtamimab, CAEL-101, Melflufen, Elotuzumab, Evomela, Pomalidomide, and others

Scope of the AL Amyloidosis Market Report

  • Therapeutic Assessment: AL Amyloidosis current marketed and emerging therapies
  • AL Amyloidosis Market Dynamics: AL Amyloidosis market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, AL Amyloidosis Market Access and Reimbursement

Discover more about drugs for AL amyloidosis in development @AL Amyloidosis Clinical Trials

Table of Contents

1.

AL Amyloidosis Market Key Insights

2.

AL Amyloidosis Market Report Introduction

3.

AL Amyloidosis Market Overview at a Glance

4.

AL Amyloidosis Market Executive Summary

5.

Disease Background and Overview

6.

AL Amyloidosis Treatment and Management

7.

AL Amyloidosis Epidemiology and Patient Population

8.

Patient Journey

9.

AL Amyloidosis Emerging Drugs

10.

Seven Major AL Amyloidosis Market Analysis

11.

AL Amyloidosis Market Outlook

12.

Potential of Current and Emerging Therapies

13.

KOL Views

14.

AL Amyloidosis Market Drivers

15.

AL Amyloidosis Market Barriers

16.

Unmet Needs

17.

SWOT Analysis

18.

Appendix

19.

DelveInsight Capabilities

20.

Disclaimer

21.

About DelveInsight

Related Reports

AL Amyloidosis Epidemiology Forecast

AL Amyloidosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the AL amyloidosis epidemiology trends.

AL Amyloidosis Pipeline

AL Amyloidosis Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key AL amyloidosis companies, including Acrotech biopharma, Sanofi, Astellas Pharma GmbH, Prothena, Alexion Pharmaceuticals, Celgene Corporation, among others.

Multiple Myeloma Market

Multiple Myeloma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key multiple myeloma companies, including Novartis, Incyte Corporation, Arcellx, Pfizer, among others.

Multiple Myeloma Pipeline

Multiple Myeloma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple myeloma companies, including Novartis, Incyte Corporation, Arcellx, Pfizer, among others.

Hodgkin Lymphoma Market

Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Hodgkin lymphoma companies, including 4SC, ACD Therapeutics, TG Therapeutics, among others.

Hodgkin Lymphoma Pipeline

Hodgkin Lymphoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Hodgkin lymphoma companies, including 4SC, ACD Therapeutics, TG Therapeutics, among others.

Other Trending Reports

Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | CAR-T Pipeline Insight | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Outlook Report | Crows Feet Market Insight | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market

Browse through our latest blog to get more insights on AL Amyloidosis Treatment Landscape

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services 

Contact Us

Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg 

Modal title

Also from this source

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

DelveInsight's Bispecifics/BiTE Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding ...

Traumatic Brain Injury Market to Expand at a CAGR of 10.9% During the Study Period (2020-2034) Fueled by Advances in Treatment and Growing Healthcare Investments | DelveInsight

Traumatic Brain Injury Market to Expand at a CAGR of 10.9% During the Study Period (2020-2034) Fueled by Advances in Treatment and Growing Healthcare Investments | DelveInsight

DelveInsight's Traumatic Brain Injury Market Insights report includes a comprehensive understanding of current treatment practices, traumatic brain...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.